CClinicalTrials.gg
RecruitingNCT05942885HYCVAUpdated Sep 11, 2025

Hypnosis: a Path to Appeasement

An interventional study of anxiety questionnaire in Hematologic Cancer, sponsored by Hospices Civils de Lyon. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-11.

Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by Apr 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 2 years 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Hypnosis is a technique allowing the patient to focus his mental attention on a thought or a sensation, with the aim of reducing or modulating the intensity of a negative feeling or an ordeal encountered during the course of treatment. This tool can be used when patients are faced with chronic disorders (pain, anxiety, ...) or iatrogenic effects (nausea, asthenia, ...).

The patient is referred to hypnosis care by the doctor, psychologist or paramedics who follow him, when they detect a need.

Several scientific studies have shown the effectiveness of hypnosis in improving the quality of life of patients with breast cancer and in reducing pain during invasive procedures. On the other hand, in hematology, no research has measured the evolution of anxiety, over time, in patients receiving hypnotherapy.

02

Conditions studied

  • Hematologic Cancer

Keywords

  • hypnosis
  • Diffuse large cell B-cell lymphoma
  • follicular lymphoma
  • anxiety
03

In context

Hematologic Neoplasms

1,464 studies on the registry are indexed under Hematologic Neoplasms; 433 are open to participants now.

This study's planned enrollment of 50 is above the median of 45 across 1,068 interventional studies indexed under Hematologic Neoplasms.

Browse Hematologic Neoplasms studies →

Lead sponsor

Hospices Civils de Lyon is the lead sponsor of 1,826 studies on the registry; 439 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients over 18 years old, fluent in French.
  • Patients starting hypnotherapy for anxiety disorders.
  • Anxiety score on the HADS scale (Hospital Anxiety and Depression Scale) greater than or equal to 8/21
  • Patients with diffuse large cell B-cell lymphoma or follicular lymphoma, whatever the stage of the disease.
  • Diagnosis announcement less than 2 months old

Exclusion criteria

Exclusion Criteria:

  • Persons deprived of their liberty by a judicial or administrative decision
  • Adults subject to a legal protection measure
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Anxiety scores

    Other: anxiety questionnaire

Interventions

  • Otheranxiety questionnaire

    Patient undergoing hypnosis session will have their anxiety measured just before the third session of hypnosis and after during a telephonic consultation. The result will be compared to the anxiety level before the first hypnosis session

06

What researchers measure

Primary outcomes

  1. Evolution of anxiety

    Difference in anxiety measured before starting hypnotherapy care and after 2 hypnosis sessions. It will be measured by the Hospital Anxiety and Depression Scale. This scale gives a score according to the level of anxiety ranging from 0 to 21. The higher the score, the more the patient is anxious.

    Time frame: Week 6 after 2 hypnosis sessions

Secondary outcomes

  1. Evolution of anxiety before hypnotherapy and after 3 months of follow-up in hypnotherapy

    Difference in anxiety measured before starting hypnotherapy care and after 3 hypnosis sessions. It will be measured by the Hospital Anxiety and Depression Scale. This scale gives a score according to the level of anxiety ranging from 0 to 21. The higher the score, the more the patient is anxious.

    Time frame: Month 3 after 3 hypnosis sessions

  2. Evolution of anxiety between D0 and M3 according to the type of lymphoma

    Difference in anxiety measured before starting hypnotherapy care and after 3 hypnosis sessions for two subgroups : follicular lymphoma and diffuse large b-cell lymphoma. It will be measured by the Hospital Anxiety and Depression Scale. This scale gives a score according to the level of anxiety ranging from 0 to 21. The higher the score, the more the patient is anxious.

    Time frame: Month 3 after 3 hypnosis sessions

  3. Evolution of anxiety between D0 and W6 according to the type of lymphoma

    Difference in anxiety measured before starting hypnotherapy care and after 2 hypnosis sessions for two subgroups : follicular lymphoma and diffuse large b-cell lymphoma. It will be measured by the Hospital Anxiety and Depression Scale. This scale gives a score according to the level of anxiety ranging from 0 to 21. The higher the score, the more the patient is anxious.

    Time frame: Week 6 after 2 hypnosis sessions

  4. Evolution of anxiety between D0 and W6 according to the gender of the patient

    Difference in anxiety measured before starting hypnotherapy care and after 2 hypnosis sessions for two subgroups : man and woman. It will be measured by the Hospital Anxiety and Depression Scale. This scale gives a score according to the level of anxiety ranging from 0 to 21. The higher the score, the more the patient is anxious.

    Time frame: Week 6 after 2 hypnosis sessions

  5. Evolution of anxiety between D0 and M3 according to the gender of the patient

    Difference in anxiety measured before starting hypnotherapy care and after 3 hypnosis sessions for two subgroups : man and woman. It will be measured by the Hospital Anxiety and Depression Scale. This scale gives a score according to the level of anxiety ranging from 0 to 21. The higher the score, the more the patient is anxious.

    Time frame: Month 3 after 3 hypnosis sessions

  6. Evolution of anxiety between D0 and W6 according to age category

    Difference in anxiety measured before starting hypnotherapy care and after 2 hypnosis sessions for two subgroups : under 60 years old ans over 60 years old. It will be measured by the Hospital Anxiety and Depression Scale. This scale gives a score according to the level of anxiety ranging from 0 to 21. The higher the score, the more the patient is anxious.

    Time frame: Week 6 after 2 hypnosis sessions

  7. Evolution of anxiety between D0 and M3 according to age category

    Difference in anxiety measured before starting hypnotherapy care and after 3 hypnosis sessions for two subgroups : under 60 years old ans over 60 years old. It will be measured by the Hospital Anxiety and Depression Scale. This scale gives a score according to the level of anxiety ranging from 0 to 21. The higher the score, the more the patient is anxious.

    Time frame: Month 3 after 3 hypnosis sessions

07

Study locations

1 of 1 sites recruiting
  • Service MB1 - Hôpital Lyon Sud - HCL
    Lyon, Pierre-Bénite 69495, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05942885
Lead sponsor
Hospices Civils de Lyon
Responsible party
Sponsor
First posted
Jul 12, 2023
Start date
Oct 30, 2023
Primary completion
Apr 30, 2026 (estimated)
Completion
Jul 30, 2026 (estimated)
Last update
Sep 11, 2025

Study contacts

Thomas BERT
Contact
thomas.bert01@chu-lyon.fr
04.78.86.43.45
Thomas BERT
principal investigator · Hospices Civils de Lyon

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion